Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13062547 | 0.97 | HRH3 (0.48) | CYP2D6KMT2ACARM1PRMT6PRMT8 | |
| SCHEMBL10294630 | 0.97 | CYP2D6 (0.46) | CYP2D6KMT2ACARM1PRMT6PRMT8 | |
| SCHEMBL13061597 | 0.94 | HRH3 (0.50) | CYP2D6KMT2ACARM1PRMT6PRMT8 | |
| SCHEMBL19679816 | 0.88 | KMT2A (0.48) | CYP2D6KMT2AHRH3CHRNA7HSD11B1 | |
| SCHEMBL1044668 | 0.88 | KMT2A (0.46) | CYP2D6KMT2APOLBCHRNA7HSD11B1 | |
| SCHEMBL1045372 | 0.88 | KMT2A (0.46) | CYP2D6KMT2APOLBCHRNA7HSD11B1 | |
| SCHEMBL19679818 | 0.88 | KMT2A (0.46) | CYP2D6KMT2APOLBCHRNA7HSD11B1 | |
| SCHEMBL577863 | 0.88 | KMT2A (0.46) | CYP2D6KMT2APOLBCHRNA7HSD11B1 | |
| SCHEMBL577083 | 0.88 | KMT2A (0.46) | CYP2D6KMT2APOLBCHRNA7HSD11B1 | |
| SCHEMBL19679814 | 0.88 | KMT2A (0.46) | CYP2D6KMT2APOLBCHRNA7HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317644-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317644-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | CYP2D6 307/4885KMT2A 1686/4885CARM1 4617/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | CYP2D6 307/4885KMT2A 1686/4885CARM1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.